关注
James Kochenderfer
James Kochenderfer
在 mail.nih.gov 的电子邮件经过验证
标题
引用次数
引用次数
年份
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
DW Lee, JN Kochenderfer, M Stetler-Stevenson, YK Cui, C Delbrook, ...
The Lancet 385 (9967), 517-528, 2015
31992015
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric …
JN Kochenderfer, ME Dudley, SH Kassim, RPT Somerville, RO Carpenter, ...
Journal of clinical oncology 33 (6), 540-549, 2015
19232015
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
JN Kochenderfer, ME Dudley, SA Feldman, WH Wilson, DE Spaner, ...
Blood, The Journal of the American Society of Hematology 119 (12), 2709-2720, 2012
18052012
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
JN Kochenderfer, WH Wilson, JE Janik, ME Dudley, M Stetler-Stevenson, ...
Blood, The Journal of the American Society of Hematology 116 (20), 4099-4102, 2010
16322010
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma
N Raje, J Berdeja, YI Lin, D Siegel, S Jagannath, D Madduri, M Liedtke, ...
New England Journal of Medicine 380 (18), 1726-1737, 2019
14822019
Toxicities of chimeric antigen receptor T cells: recognition and management
JN Brudno, JN Kochenderfer
Blood, The Journal of the American Society of Hematology 127 (26), 3321-3330, 2016
13452016
T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
SA Ali, V Shi, I Maric, M Wang, DF Stroncek, JJ Rose, JN Brudno, ...
Blood, The Journal of the American Society of Hematology 128 (13), 1688-1700, 2016
8032016
Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management
JN Brudno, JN Kochenderfer
Blood reviews 34, 45-55, 2019
7642019
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma
RO Carpenter, MO Evbuomwan, S Pittaluga, JJ Rose, M Raffeld, S Yang, ...
Clinical cancer research 19 (8), 2048-2060, 2013
7252013
T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma
JN Brudno, I Maric, SD Hartman, JJ Rose, M Wang, N Lam, ...
Journal of Clinical Oncology 36 (22), 2267-2280, 2018
7142018
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
JN Kochenderfer, ME Dudley, RO Carpenter, SH Kassim, JJ Rose, ...
Blood, The Journal of the American Society of Hematology 122 (25), 4129-4139, 2013
7022013
Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell …
JN Brudno, RPT Somerville, V Shi, JJ Rose, DC Halverson, DH Fowler, ...
Journal of clinical oncology 34 (10), 1112-1121, 2016
6562016
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
JN Kochenderfer, SA Rosenberg
Nature reviews Clinical oncology 10 (5), 267-276, 2013
5912013
Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels
JN Kochenderfer, RPT Somerville, T Lu, V Shi, A Bot, J Rossi, A Xue, ...
Journal of clinical oncology 35 (16), 1803-1813, 2017
5632017
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor
JN Kochenderfer, SA Feldman, Y Zhao, H Xu, MA Black, RA Morgan, ...
Journal of immunotherapy 32 (7), 689-702, 2009
5442009
Chimeric antigen receptor T-cell therapies for lymphoma
JN Brudno, JN Kochenderfer
Nature reviews Clinical oncology 15 (1), 31-46, 2018
4862018
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
JN Kochenderfer, Z Yu, D Frasheri, NP Restifo, SA Rosenberg
Blood, The Journal of the American Society of Hematology 116 (19), 3875-3886, 2010
4362010
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity
Y Zhao, QJ Wang, S Yang, JN Kochenderfer, Z Zheng, X Zhong, ...
The Journal of Immunology 183 (9), 5563-5574, 2009
4192009
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
M Sabatino, J Hu, M Sommariva, S Gautam, V Fellowes, JD Hocker, ...
Blood, The Journal of the American Society of Hematology 128 (4), 519-528, 2016
3682016
Long-term outcomes following CAR T cell therapy: what we know so far
KM Cappell, JN Kochenderfer
Nature reviews Clinical oncology 20 (6), 359-371, 2023
3042023
系统目前无法执行此操作,请稍后再试。
文章 1–20